Related Experiment Video
Updated: Aug 18, 2026

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
Published on: July 16, 2012
[Coinfection with hepatitis G virus in chronic hepatitis C. Response to treatment with interferon alpha]
D Quintero1, J Salmerón, A Palacios
1Servicio de Aparato Digestivo, Hospital Clínico San Cecilio, Granada.
Insights
Hepatitis G virus (HGV) co-infection is common in chronic hepatitis C (CHC) patients but does not worsen liver disease or affect interferon treatment response. HGV is more sensitive to interferon than hepatitis C virus (HCV).
Area of Science:
- Hepatology
- Virology
- Immunology
Context:
- Hepatitis C virus (HCV) is a major cause of chronic liver disease.
- The impact of Hepatitis G virus (HGV) co-infection on HCV pathogenesis and treatment outcomes remains incompletely understood.
- Assessing co-infection prevalence and its clinical significance is crucial for effective patient management.
Purpose:
- To determine the prevalence of HGV co-infection in patients with chronic hepatitis C (CHC).
- To analyze the clinical, epidemiological, and histological characteristics of co-infected patients.
- To evaluate the impact of HGV co-infection on the response to interferon (IFN) therapy in CHC patients.
Summary:
- A study of 180 CHC patients found an HGV co-infection prevalence of 12.2%.
- No significant differences were observed in clinical, biochemical, or histological parameters between HGV-negative and HGV-positive groups.
- Interferon treatment response rates for HCV were similar in both groups, suggesting HGV does not alter treatment efficacy.
Impact:
- HGV co-infection does not appear to increase HCV pathogenicity or negatively impact interferon treatment response.
- HGV demonstrates higher sensitivity to interferon than HCV, though this did not translate to improved overall treatment outcomes in co-infected patients.
- Routine HGV testing is deemed unnecessary for patients with chronic hepatitis C based on these findings.
Background:
It is thought that the cytopathic effect of HGV is not important. Nevertheless, the cytopathic effect on liver is less known in the cases of co-infection with HCV. The aim was to study the prevalence of co-infection in patients with chronic hepatitis C (CHC) and to analyse the clinical-epidemiological and histological data and the interferon (IFN) response.
Patients And Methods:
We included 180 patients with CHC and the HGV-RNA was determined.
Results:
The prevalence of co-infection was 12.2% (n = 22). No statistical differences were observed between the non co-infected and co-infected groups with regard to the age, sex, mechanism of transmission and alcohol abuse. Also, there were no differences in the hepatic biochemical, no organ-specific antibodies, histological lesions and Knodell index. The HCV biochemical response (BR) and virological response (VR) after 6 months post-IFN were the same in both groups (HGV negative: BR = 29%, VR = 12%; HGV positive: BR = 22%, VR = 18%). HGV was determined after 6 months posttreatment in the co-infected group (first cycle of IFN, n = 22; second cycle of IFN, n = 9): 12 (55%) were HGV-RNA negative and 5 (23%) HCV-RNA negative, (p = 0.021). When we compared the BR vs VR in this group, there were 12 HGV-RNA negative but only two had BR (NS). On the contrary, the BR was related to HCV-RNA negative (p = 0.023).
Conclusion:
The prevalence of HGV co-infection is important in our area (12.8%). The HGV does not increase the pathogenicity of HCV and does not change the IFN response, although the HGV is more IFN sensible than HCV. The determination of HGV is not necessary in patients with HCV.
Related Concept Videos
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Viruses with RNA Genomes
Cytomegalovirus Disease
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction

